Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescript...
Study in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in Spain
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 150
- Registration Number
- NCT06415175
- Locations
- 🇪🇸
Investigational Site Number : 7240008, Seville, Sevilla, Spain
🇪🇸Investigational Site Number : 7240003, Barcelona, Spain
🇪🇸Investigational Site Number : 7240012, Palma de Mallorca, Spain
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Monotherapy Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
- First Posted Date
- 2024-05-09
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 961
- Registration Number
- NCT06407934
- Locations
- 🇺🇸
Paddington Testing Company- Site Number : 8401041, Philadelphia, Pennsylvania, United States
🇦🇷Investigational Site Number : 0320005, Buenos Aires, Argentina
🇨🇦Investigational Site Number : 1240031, Edmonton, Alberta, Canada
Study in Adults With Severe Chronic Rhinosinusitis With Nasal Polyposis Treated With Dupilumab in France
- Conditions
- Interventions
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 150
- Registration Number
- NCT06393946
- Locations
- 🇫🇷
Investigational Site Number: 250.0001, Nantes, France
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
- Conditions
- Interventions
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 2500
- Registration Number
- NCT06372145
- Locations
- 🇺🇸
Springfield Clinic 1st - 800 Building- Site Number : 8400071, Springfield, Illinois, United States
🇺🇸Hope Neurology- Site Number : 8409904, Knoxville, Tennessee, United States
🇺🇸Neurology Center of San Antonio- Site Number : 8400036, San Antonio, Texas, United States
A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 64
- Registration Number
- NCT06356571
A Food Effect and Relative Bioavailability Study of Rilzabrutinib in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 28
- Registration Number
- NCT06342700
- Locations
- 🇺🇸
Nucleus Network Site Number : 8400001, Saint Paul, Minnesota, United States
A Study to Test if SAR443809 is Tolerated and Safe When Taken as a Single Dose in Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2024-03-22
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 54
- Registration Number
- NCT06326814
- Locations
- 🇺🇸
Parexel International Site Number : 8400002, Glendale, California, United States
🇺🇸Parexel International Site Number : 8400003, Baltimore, Maryland, United States
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
- First Posted Date
- 2024-03-05
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 18
- Registration Number
- NCT06293053
- Locations
- 🇺🇸
Mission Dermatology Center- Site Number : 8400011, Rancho Santa Margarita, California, United States
🇺🇸Pediatric Center Of Excellence- Site Number : 8400005, Coral Gables, Florida, United States
🇺🇸USF Health - Dermatology and Cutaneous Surgery - Davis Blvd Location (Pediatric Dermatology)- Site Number : 8400003, Tampa, Florida, United States
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Conditions
- Interventions
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 160
- Registration Number
- NCT06290141
- Locations
- 🇧🇷
PSEG Centro de Pesquisa Clinica Site Number : 0760009, Sao Paulo, São Paulo, Brazil
🇨🇿Investigational Site Number : 2030002, Pardubice, Czechia
🇨🇿Investigational Site Number : 2030001, Praha 2, Czechia
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
- Conditions
- Interventions
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 140
- Registration Number
- NCT06290128
- Locations
- 🇺🇸
NeuroMedical Clinic of Central Louisiana- Site Number : 8400031, Alexandria, Louisiana, United States
🇺🇸Henry Ford Hospital- Site Number : 8400025, Detroit, Michigan, United States
🇺🇸Columbia University Irving Medical Center- Site Number : 8400003, New York, New York, United States